lipocine

  1. Nelson Vergel

    Oral Testosterone Product Phase 3 Study Completed

    LPCN 1021 is a twice-a-day, oral testosterone product candidate with three simple oral dosing options that we expect will overcome the major shortcomings of existing products. Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the completion of the last patient...
Top